Orion Portfolio Solutions LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Orion Portfolio Solutions LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 129.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,323 shares of the biopharmaceutical company’s stock after buying an additional 747 shares during the period. Orion Portfolio Solutions LLC’s holdings in Regeneron Pharmaceuticals were worth $801,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. boosted its stake in Regeneron Pharmaceuticals by 4.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 412 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 16 shares during the last quarter. Colony Group LLC raised its holdings in Regeneron Pharmaceuticals by 0.4% in the 2nd quarter. Colony Group LLC now owns 4,988 shares of the biopharmaceutical company’s stock worth $2,786,000 after purchasing an additional 18 shares during the period. Kistler Tiffany Companies LLC raised its holdings in Regeneron Pharmaceuticals by 19.6% in the 3rd quarter. Kistler Tiffany Companies LLC now owns 110 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 18 shares during the period. Valeo Financial Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 5.2% in the 3rd quarter. Valeo Financial Advisors LLC now owns 383 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 19 shares during the period. Finally, Essex Investment Management Co. LLC raised its holdings in Regeneron Pharmaceuticals by 0.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 6,444 shares of the biopharmaceutical company’s stock worth $3,900,000 after purchasing an additional 21 shares during the period. Institutional investors own 82.99% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock opened at $615.24 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $441.00 and a 1 year high of $686.62. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.16 and a current ratio of 3.71. The company has a market capitalization of $66.16 billion, a P/E ratio of 9.82, a PEG ratio of 0.99 and a beta of 0.18. The company’s fifty day moving average is $633.79 and its two-hundred day moving average is $617.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, November 4th. The biopharmaceutical company reported $15.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $9.81 by $5.56. The business had revenue of $3.45 billion for the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 51.65% and a return on equity of 50.38%. The business’s quarterly revenue was up 50.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $7.68 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 66.87 earnings per share for the current year.

In related news, CFO Robert E. Landry sold 781 shares of the company’s stock in a transaction that occurred on Friday, December 10th. The shares were sold at an average price of $666.42, for a total transaction of $520,474.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, November 16th. The stock was sold at an average price of $647.17, for a total transaction of $4,638,267.39. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,095 shares of company stock worth $21,716,542. 11.84% of the stock is owned by insiders.

A number of research firms have commented on REGN. Cowen began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 7th. They set a “market perform” rating and a $625.00 price target on the stock. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $660.00 target price for the company in a research report on Monday, January 3rd. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $571.00 to $617.00 and gave the company an “equal weight” rating in a research note on Friday, November 5th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $760.00 and gave the company an “overweight” rating in a research note on Wednesday, November 10th. Finally, Benchmark downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $729.33.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Read More: Why do companies issue convertible shares?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.